Programme

  1. Registration and coffee

  2. Welcome and introduction by the moderator

  3. KEYNOTE: Recent developments in EU chemicals legislation from a high-level perspective

    • REACH/CLP revision
    • REFIT
    • New EU Parliament 
  4. Session 1: Overviews

  5. EU Commission overview

    • Extension of the review program
    • New (draft) Delegated Regulation on the work program for the systematic examination of all existing active substances
    • Amendments to the regulations on changes (Regulation 354/2013), same biocidal products (Regulation 414/2013) and renewals under mutual recognition (Regulation 492/2014)
    • Approach to setting of maximum residue levels for biocides
    • Grants to member states for the implementation of the BPR
  6. ECHA overview

    • Recent developments
    • Future challenges
  7. Enforcement projects of the ECHA Forum BPR subgroup

    • Labels of biocidal products
    • Insight into related BEF-2 project results from 2022
    • Focus on labels in the BEF-3 project in 2025
    • Routine inspection focus on forbidden label claims  
  8. Refreshment break

  9. Member state overview

    • Capacity planning
    • Structure and best practice at the BAuA: Expectations, experiences and challenges
  10. Industry overview

    • The 3rd extension of the review program
    • New review regulation replacing Regulation (EU) No 1062/2014
    • Pros and cons, and expected practical impact
  11. Q&A session

  12. Lunch and networking

  13. Session 2: Current state of science for testing under the BPR

  14. How the BPR will be potentially affected by the revision of PBT and vPvB guidance

    • Background PBT/vPvB substances under REACH
    • Implications for biocides
    • Case study examples
  15. Special focus on NAMs and ED

  16. Regulatory acceptance of NAMs, what is already acceptable and what should be developed to make sure the NAMs will be accepted

    • Challenges of using NAMs for risk assessment for biocidal products
    • Read across as a tool for endocrine disrupter assessment for biocidal substances
    • Examples and recommendations
  17. Regulatory acceptance of NAMs, what is already acceptable and what should be developed to make sure the NAMs will be accepted

    • NAMs with regulatory acceptance in biocides assessments so far
    • PARC and other initiatives: are low hanging fruit to be expected?
    • Requirements to speed up the transformation
  18. Satisfying data requirements under the BPR using Non-Animal Methods (NAMs)

    • Validated and regulatory accepted NAMs 
    • Moving forward: How to assess more complex endpoints
    • Troubleshooting and sharing successful experiences 
  19. Status quo of acceptance and use of NAMs in European regulatory risk assessment

    • Barriers and drivers of acceptance and use
    • Overarching views of the public and risk assessors of current practices in regulatory toxicology
  20. Refreshment break

  21. Q&A and panel discussion: How to achieve greater regulatory acceptance of NAMs for biocides

  22. Session 3: Important efficacy updates

  23. PT6 efficacy for yeast and fungi

    • Normative view
    • PT6 efficacy study design
    • Typical troubleshooting
    • Cases studies  
  24. Q&A session

  25. Networking drinks reception

  26. Close of day one